Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Bioorg Med Chem. 2016 Nov 10;25(3):813–824. doi: 10.1016/j.bmc.2016.11.013

Table 6.

RpMetAP Inhibitory Compounds Tested in EC Culture Infection Model

Compound MW a Stock (mM) b Test Range (µM) c Growth Inhibition d
(10) 222.63 100 300, 30, 3, 0.3 No
(11) 257.07 100 300, 30, 3, 0.3 No
(12) 206.27 100 300, 30, 3, 0.3 Yes
(13) 220.30 100 300, 30, 3, 0.3 Yes
(14) 224.26 100 300, 30, 3, 0.3 Yes
(15) 240.72 100 300, 30, 3, 0.3 Yes
(16) 240.72 100 300, 30, 3, 0.3 Yes
(17) 275.16 100 30, 3, 0.3, 0.03 No
(18) 248.35 100 30, 3, 0.3, 0.03 No
(19) 262.37 100 30, 3, 0.3, 0.03 No
(20) 195.65 100 3, 0.3, 0.03, 0.003 No
(21) 181.62 100 30, 3, 0.3, 0.03 Yes
(22) 245.06 100 30, 3, 0.3, 0.03 Yes
(23) 190.16 100 3, 0.3, 0.03, 0.003 No
(24) 315.20 40 20, 2, 0.2, 0.02 No
(25) 362.25 25 7.5, 0.75, 0.075, 0.0075 No
(26) 325.75 100 3, 0.3, 0.03, 0.003 Yes
a

Compound Molecular Weight in g/mol.

b

Stock inhibitor solutions were initially prepared in 100% DMSO to achieve a 100 mM concentration. Compounds that were insoluble at 100 mM were adjusted by addition of DMSO until solubility was achieved.

c

All compounds were initially tested for toxicity against uninfected ECs. Working concentration test ranges that produced no EC toxicity were selected for further testing against R. prowazekii-infected ECs.

d

Inhibition of rickettsial growth was determined using the in vitro host EC viability assay described in the Experimental Methods section.